Key result
MVP in competitive athletes carries a ~0.5% annual clinical event rate with no SCD.
Cohort (n=7,449)
No
In competitive athletes, mitral valve prolapse has a prevalence of 2.9% and is associated with a low rate of major cardiovascular events (0.5%/year) and no sudden cardiac death over long-term follow-up.
Supports low-risk profile for athletes with MVP; extends observational data but leaves open need for prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Caselli et al. (2018) conducted a cohort in Mitral valve prolapse (n=7,449). Mitral valve prolapse vs. Athletes without mitral valve prolapse was evaluated on Clinical events (mitral valve surgery, ischemic stroke, atrial fibrillation requiring hospitalization, sudden cardiac death). In competitive athletes with mitral valve prolapse, the long-term clinical event rate was 0.5% per year over 8 years, with no sudden cardiac deaths recorded.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: